Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)

Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)

  • CN 102,933,711 A
  • Filed: 01/13/2011
  • Published: 02/13/2013
  • Est. Priority Date: 05/03/2010
  • Status: Active Grant
First Claim
Patent Images

1. the reticent function of albumen (SIRT) polynucleotide and/or the method for expression of regulating in the body or in the external adjusting patient cell or tissue, described method comprises:

  • be that at least a antisense oligonucleotide of 5 to 30 Nucleotide contacts with described cell or tissue and length, wherein said at least a oligonucleotide with comprise the Nucleotide 1 to 1028 of SEQ ID NO;

    9 or the Nucleotide 1 to 429 of SEQID NO;

    10, or the Nucleotide 1 to 593 of the Nucleotide 1 to 508 of SEQ ID NO;

    11 or SEQ ID NO;

    12,1 to 373 of SEQ ID NO;

    13,1 to 1713 of SEQ IDNO;

    14,1 to 660 of SEQ ID NO;

    15,1 to 589 of SEQ ID NO;

    16,1 to 726 of SEQ ID NO;

    17,1 to 320 of SEQ ID NO;

    18,1 to 616 of SEQ IDNO;

    19,1 to 492 of SEQ ID NO;

    20,1 to 428 of SEQ ID NO;

    21,1 to 1757 or the SEQ IDNO;

    143 of 1 to 2714 or the SEQ ID NO;

    142 of 1 to 705 or the SEQ ID NO;

    141 of 1 to 4041 or the SEQ ID NO;

    23 of SEQ ID NO;

    22 1 to 3647 in the reverse complementary sequence of polynucleotide of 5 to 30 continuous nucleotides have at least 50% sequence identity;

    Thereby reticent function and/or the expression of regulating albumen (SIRT) polynucleotide described in the interior or external adjusting of the body patient cell or tissue.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×